Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06403644 · ClinicalTrials.gov registry record · NA
Evaluating the Technology and Assessing the Biological Effects of Commercially Available PhotoBioModulation Devices
A NA study of Physiological Wellness, sponsored by United States Air Force Research Laboratory.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06403644: Recruiting NA study of Physiological Wellness, sponsored by United States Air Force Research Laboratory.
NCT06403644 is a NA study of Physiological Wellness that is actively recruiting participants, run by United States Air Force Research Laboratory. The registered enrollment target is 150 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06403644, a NA study of Physiological Wellness, is actively recruiting participants, sponsored by United States Air Force Research Laboratory.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Photobiomodulation therapy (PBMT) involves applying non-ionizing forms of light from sources including lasers, LEDs, and broadband light, in the visible and near infrared spectrum, to the body to enhance performance, stimulate healing, modulate recovery, and improve health. The investigators will conduct a single-blinded randomized-control trial with sham control to investigate the effectiveness of providing PBMT in a military population, translating this cutting-edge research to application in the operational setting.
Primary Outcome
Changes in blood biomarkers (MSD proinflammatory panel: IL-1beta, IL-2, IL-6, IL-12p70, IL-17A, IFN-gamma, and TNF-alpha) compared across the sham and active PBMT conditions. As elevated proinflammatory cytokine levels may be a sign of heightened inflammation, lower proinflammatory cytokine levels at the end of the active condition compared to the beginning of the block, along with no statistical change at the end of the sham block condition compared to the beginning of the sham block, may indic
Conditions Studied
Interventions
- DEVICE NovoTHOR XL Photobiomodulation Full Body Light Bed
- DEVICE ARRC LED Photobiomodulation Full Body Light Bed
Study Locations (1)
Ohio
- Wright Patterson Air Force Base - Beavercreek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2028-09-01 |
| Phase | NA |
What NCT06403644 shows while recruiting
NCT06403644 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Physiological Wellness appearing as the primary indexed condition, and to 2 interventions - of which NovoTHOR XL Photobiomodulation Full Body Light Bed is the first listed.
NCT06403644 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06403644 about?
NCT06403644 is a clinical study titled "Evaluating the Technology and Assessing the Biological Effects of Commercially Available PhotoBioModulation Devices". Photobiomodulation therapy (PBMT) involves applying non-ionizing forms of light from sources including lasers, LEDs, and broadband light, in the visible and near infrared spectrum, to the body to enhance performance, stimulate healing, modulate recovery, and improve health. The investigators will co...
What is the current status of trial NCT06403644?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-03-11. Estimated completion is 2028-09-01.
What conditions does trial NCT06403644 study?
This clinical trial studies the following conditions: Physiological Wellness.
What interventions are being tested in trial NCT06403644?
The interventions under investigation include: NovoTHOR XL Photobiomodulation Full Body Light Bed (DEVICE), ARRC LED Photobiomodulation Full Body Light Bed (DEVICE).
Who is sponsoring clinical trial NCT06403644?
This trial is sponsored by United States Air Force Research Laboratory, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06403644 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06403644's enrollment target sits among peer trials
150 661st of 2000 higher than 1,299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI